Changeflow GovPing Pharma & Healthcare Inulin-Spirulina Co-intervention for Insomnia D...
Routine Notice Added Final

Inulin-Spirulina Co-intervention for Insomnia Disorder

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH National Library of Medicine registered a clinical trial (NCT07537192) on ClinicalTrials.gov investigating inulin and spirulina dietary supplements as co-interventions for insomnia disorder in adults aged 18 to 60 years. The 12-week randomized controlled trial will enroll participants in four arms (inulin, spirulina, combined, placebo) and measure sleep quality, mood, anxiety, and cognitive outcomes. Researchers will monitor adverse events and collect polysomnography and biospecimen data at baseline and week 12.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH registered a new clinical trial (NCT07537192) on ClinicalTrials.gov studying inulin and spirulina dietary supplements as interventions for insomnia disorder in adults aged 18-60. The 12-week randomized controlled trial will evaluate four groups (inulin alone, spirulina alone, combined treatment, placebo) using sleep quality scores, polysomnography, and biospecimen collection as primary endpoints.

Institutions conducting dietary supplement or insomnia disorder research should note this trial registration for compliance awareness. Sponsors and investigators conducting applicable clinical trials should verify NIH ClinicalTrials.gov registration requirements are met, including appropriate study design classification and adverse event monitoring protocols per GxP standards.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Inulin-Spirulina Co-intervention for Insomnia Disorder

N/A NCT07537192 Kind: NA Apr 17, 2026

Abstract

The goal of this clinical trial is to learn if inulin and spirulina, used alone or in combination, can improve insomnia disorder in adults aged 18 to 60 years with chronic insomnia disorder. It will also learn about the safety of these interventions. The main questions it aims to answer are:

Does inulin plus spirulina improve sleep quality, as measured by the reduction rate in Pittsburgh Sleep Quality Index (PSQI) score? Does the intervention improve sleep-related, mood, anxiety, and cognitive outcomes after 12 weeks? Researchers will compare an inulin group, a spirulina group, a combined inulin plus spirulina group, and a placebo group to see if the combined intervention provides greater benefit than either single intervention or placebo.

Participants will:

be randomly assigned to 1 of 4 groups: inulin, spirulina, inulin plus spirulina, or placebo; take the assigned study product once daily for 12 weeks; complete sleep, mood, anxiety, and cognitive assessments at baseline and week 12; undergo polysomnography and provide blood and stool samples at baseline and week 12; and be monitored for adverse events throughout the study.

Conditions: Insomnia Disorder, Sleep Initiation and Maintenance Disorders

Interventions: Inulin, Spirulina, Maltodextrin

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 17th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
NCT07537192

Who this affects

Applies to
Pharmaceutical companies Clinical investigators Healthcare providers
Industry sector
3254.1 Biotechnology
Activity scope
Dietary supplement research Clinical trial registration Sleep disorder investigation
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Public Health Healthcare

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!